To this end, CML-cell lines and CD34+ blast cells harvested from CML patients, were cultured with a TK inhibitor (STI571) both alone and in combination with other anti-leukaemic agents. This evidence concerns the gene TKT and chronic myelogenous leukemia, BCR-ABL1 positive.